.css-1gu7o1h p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1gu7o1h .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-1hgicv7{box-sizing:border-box;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}.css-1hgicv7 p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1hgicv7 .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}

JavaScript is currently disabled in your browser. For the best experience, please enable JavaScript to enjoy full website functionality. Thank you!

Steps to Enable JavaScript

The Gilenya Pregnancy Registry

clipboard-pencil

About the study

The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.

user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Any woman with a diagnosis of MS
Any woman currently pregnant
Exposure to fingolimod during pregnancy or up to 8 weeks before LMP
Signed informed consent

EXCLUSION CRITERIA

Exclusion Criteria:

There are no specific exclusion criteria for this registry.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details

Contition

Multiple Sclerosis

Participants needed

500

Est. Completion Date

Jan 2, 2031

Treatment type

Observational [Patient Registry]

Sponsor

Novartis

ClinicalTrials.gov identifier

NCT01285479

Study number

CFTY720D2404

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?